Pneumonia risk with budesonide-containing therapies in COPD: pooled analysis of three Phase III studies

G. Ferguson (Farmington Hills, United States of America), K. Rabe (Grosshansdorf, Germany), N. Hanania (Houston, United States of America), S. Ballal (Morristown, United States of America), J. Nyberg (Morristown, United States of America), P. Darken (Morristown, United States of America), K. Deangelis (Durham, United States of America), P. Dorinsky (Durham, United States of America)

Source: International Congress 2019 – COPD clinical studies: bronchodilators, corticosteroids and more
Session: COPD clinical studies: bronchodilators, corticosteroids and more
Session type: Poster Discussion
Number: 3375

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
G. Ferguson (Farmington Hills, United States of America), K. Rabe (Grosshansdorf, Germany), N. Hanania (Houston, United States of America), S. Ballal (Morristown, United States of America), J. Nyberg (Morristown, United States of America), P. Darken (Morristown, United States of America), K. Deangelis (Durham, United States of America), P. Dorinsky (Durham, United States of America). Pneumonia risk with budesonide-containing therapies in COPD: pooled analysis of three Phase III studies. 3375

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you: